SuperworthConcentra Group Holdings Parent CON
- Market cap
- $5B
- PE
- 25.5×
- 2y median 17.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.2×
- EV/EBIT
- 17.2×
- Revenue, 12 months
- $2.3B
- +14% on a year ago
- Net margin
- 8.7%
- Free cash flow yield
- 5.3%
Concentra Group Holdings Parent trades at 25.5× trailing earnings, pricier than 99% of the last ten years. Revenue was $2.3B over the last twelve months, up 14% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $474M | $440.7M | $467.6M+3% | $477.9M+2% | $489.6M+3% | $465M+6% | $500.8M+7% | $550.8M+15% | $572.8M+17% | $539.1M+16% | $569.6M+14% | $606M+10% | |
| Cost of revenue | $336.8M | $330.9M | $337M+3% | $339.3M+3% | $351.1M+4% | $344.9M+4% | $357.1M+6% | $389.3M+15% | $405.5M+16% | $398.4M+16% | $399.1M+12% | $413.9M+6% |
| Gross profit | $137.2M | $109.8M | $130.6M+2% | $138.6M+1% | $138.5M+1% | $120.2M+9% | $143.7M+10% | $161.5M+17% | $167.3M+21% | $140.7M+17% | $170.5M+19% | $192.1M+19% |
| SG&A | $38.2M | $42.1M | $36.9M+7% | $36.8M−1% | $37.1M−3% | $45.5M+8% | $46.7M+27% | $52.9M+44% | $52.9M+43% | $50.8M+12% | $55.3M+18% | $56.7M+7% |
| $80.9M | $49.3M | $75.5M+0% | $83.9M+2% | $86.2M+7% | $59.1M+20% | $80.3M+6% | $89.5M+7% | $94.5M+10% | $69.7M+18% | $95.6M+19% | $115.1M+29% | |
| Interest expense | $64K | $113K | $111K | $9.3M | $2.7M+4105% | $25.7M+22674% | $25.5M+22916% | $28.2M+203% | $0 | $109.3M+325% | $26M+2% | $25.7M−9% |
| Pre-tax income | $69.6M | $38.8M | $65.4M+3% | $71.2M+1% | $62.2M−11% | $32.6M−16% | $53.9M−18% | $61.3M−14% | $65.8M+6% | $42.8M+31% | $69.6M+29% | $89.3M+46% |
| $15.2M | $9.9M | $15.1M−6% | $18.1M+9% | $16.4M+8% | $9.8M−1% | $13.3M−12% | $15.2M−16% | $16M−3% | $6.6M−33% | $17.3M+31% | $22M+46% | |
| Net income | $53.1M | $27.8M | $49M+6% | $51.7M−2% | $44.3M−17% | $21.5M−23% | $38.9M−21% | $44.6M−14% | $48.3M+9% | $34.7M+61% | $50.5M+30% | $65.3M+47% |
| $0.51 | $0.27 | $0.47+7% | $0.50−2% | $0.37−28% | $0.17−37% | $0.30−36% | $0.35−30% | $0.38+3% | $0.26+53% | $0.39+30% | $0.51+46% | |
| 104M | 104.1M | 104.1M+0% | 104.1M+0% | 120.8M+16% | 127.2M+22% | 128.1M+23% | 128.2M+23% | 128.2M+6% | 128.7M+1% | 128.5M+0% | 127.8M−0% |
Revenue: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them. 12 periods, Q2 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.
SG&A: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Operating income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Income tax: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Net income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q1 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY23 and Q1 FY24: share-days: the 6-month average less the second quarter's. Q4 FY23 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Concentra Group Holdings Parent's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CONConcentra Group Holdings Parent | $5B | 25.5× | 17.5× | 2.2× | +14% | 8.7% | |
| LFSTLifeStance Health | $4.9B | 99.5× | 142× | 3.1× | +20% | 3.2% | |
| SHCSotera Health | $5.2B | 31.8× | 55.4× | 4.2× | +8% | 13.4% | |
| OPCHOption Care Health | $4.7B | 23.5× | 26.4× | 0.8× | +6% | 3.7% | |
| CHEChemed | $6.7B | 25.8× | 29.0× | 2.6× | +3% | 10.6% | |
| NHCNational Healthcare | $3.7B | 26.5× | 21.4× | 2.4× | +7% | 9.0% | |
| PACSPACS | $7.5B | 27.2× | 27.2× | 1.4× | +15% | 4.8% | |
| AVAHAveanna Healthcare | $2.9B | 10.9× | 21.8× | 1.1× | +20% | 10.6% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| ENSGEnsign | $10.2B | 27.5× | 25.5× | 1.9× | +19% | 6.9% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| Peer median | $4.8B | 26.9× | 26.8× | 1.6× | +12% | 7.9% |
More on Concentra Group Holdings Parent
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .